Indonesia's PT BioFarma ready to produce IndoVac Covid-19 vaccine

PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021.

Honesti Baasyir, president director of PT BioFarma, said the company collaborated with the USA’s Baylor College of Medicine, a private, independent health sciences center in Houston, Texas, to develop IndoVac, a recombinant protein subunit vaccine produced from yeast.

PT Bio Farma has completed Phase I and Phase II clinical trials and is currently in the Phase III stage to produce the primary series vaccines or two vaccine doses for everyone aged 18 years and older.

IndoVac uses vaccine technology platforms which are compatible with the equipment and facilities within our factories. The technology platforms for protein recombinant vaccines also offer other benefits: they can be adapted to the new strains of Covid-19. Results from Phase I and Phase II clinical trials showed that IndoVac offers quality safety and efficacy, not less competitive than other Covid-19 vaccines, the company noted.

Applying for EUA permit